Next-generation sequencing for acute myeloid leukemias

Advanced testing for individualized insights

Our next-generation sequencing testing for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) offers both comprehensive and focused approaches to testing. Flexible ordering includes 4-gene, 11-gene, and 42-gene panels to meet your patients’ specific needs, with the option of add-on (reflex) analysis for the additional genes in the 42-gene panel if a smaller panel was ordered initially. The comprehensive, 42-gene panel follows World Health Organization and National Comprehensive Cancer Network guidelines for genes of clinical significance. Diagnostic, prognostic, therapeutic, or germline, our test has your patients covered.

Key testing

Additional tests

Test in Focus

David Viswanatha, M.D., gives an overview of the next-generation sequencing (NGS) testing for myeloid malignancies available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.

Learn more about how to order these evaluations at your institution.